Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
The transcription factor C/EBPalpha (for CCAAT/enhancer binding protein-alpha; encoded by the gene CEBPA) is crucial for the differentiation of granulocytes. Conditional expression of C/EBPalpha triggers neutrophilic differentiation, and no mature granulocytes are observed in Cebpa-mutant mice. Here we identify heterozygous mutations in CEBPA in ten patients with acute myeloid leukemia (AML). We found that five mutations in the amino terminus truncate the full-length protein, but did not affect a 30-kD protein initiated further downstream. The mutant proteins block wild-type C/EBPalpha DNA binding and transactivation of granulocyte target genes in a dominant-negative manner, and fails to induce granulocytic differentiation. Ours is the first report of CEBPA mutations in human neoplasia, and such mutations are likely to induce the differentiation block found in AML.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We have recently shown mutations in the DNA-binding domain of C/EBP␣ in acute myeloid leukemia, suggesting its importance in granulocyte differentiation and leukemia.19”
From Granulocyte inducer C/EBPα inactivates the myeloid master regulator PU.1: possible role in lineage commitment decisions (2002) · cites this paper as [19]
Citations
Cites
The scanning model for translation: an update.
Kozak, M. (1989) · The Journal of cell biology · doi:10.1083/jcb.108.2.229 · Cited by 3,486 · cited 1×
“These findings support the concept that CEBPA forms detected with monospecific antibodies are alternative products translated from several in-frame initiation codons by a leaky ribosome-scanning mechanis”
BackgroundThe Leucine Zipper: A Hypothetical Structure Common to a New Class of DNA Binding Proteins
Landschulz, W. H., Johnson, P. F., & McKnight, S. L. (1988) · Science · doi:10.1126/science.3289117 · Cited by 3,443
Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells.
Cao, Z., Umek, R. M., & McKnight, S. L. (1991) · Genes & Development · doi:10.1101/gad.5.9.1538 · Cited by 1,663
Chromosomal translocations in human cancer
Rabbitts, T. H. (1994) · Nature · doi:10.1038/372143a0 · Cited by 1,503
Descombes, P., & Schibler, U. (1991) · Cell · doi:10.1016/0092-8674(91)90531-3 · Cited by 990
Isolation of a recombinant copy of the gene encoding C/EBP.
Landschulz, W. H., Johnson, P. F., Adashi, E. Y., Graves, B. J., & McKnight, S. L. (1988) · Genes & Development · doi:10.1101/gad.2.7.786 · Cited by 956
Zhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910 · cited 1×
“In addition, no mature granulocytes are observed in Cebpa -mutant mice, whereas all the other blood cell types are present in normal proportion”
BackgroundSelf-citationTranscription Factors, Normal Myeloid Development, and Leukemia
Tenen, D. G., Hromas, R., Licht, J. D., & Zhang, D.-E. (1997) · Blood · doi:10.1182/blood.v90.2.489 · Cited by 735 · cited 1×
“gif" NDATA ITEM> ]> Introduction A number of oncogenes that affect proliferation and cell death have been identified in leukemias and other cancers, but relatively few differentiation genes have been implicated in the malignant phenotyp”
BackgroundSelf-citationCCAAT-Enhancer Binding Protein: A Component of a Differentiation Switch
Umek, R. M., Friedman, A. D., & McKnight, S. L. (1991) · Science · doi:10.1126/science.1987644 · Cited by 712 · cited 1×
“bThe abnormalities were one del(9)(q21), one del(9)(q22q34), one t(6;9), one t(10;21)(p11;q22), one del(7)(q22q34), one +8, one +14, and four complex abnormalities.”
BackgroundRadomska, H. S., Huettner, C. S., Zhang, P., Cheng, T., Scadden, D. T., & Tenen, D. G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.4301 · Cited by 466 · cited 1×
“cThese patients had a 46,XY,del(12)(p11.”
Self-citation
Cited by
Items 101–200 of 930
The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia
Grimwade, D. J. (2001) · Best Practice & Research Clinical Haematology · doi:10.1053/beha.2001.0152 · Cited by 179
Transcriptional regulation in acute promyelocytic leukemia
Lin, R. J., Sternsdorf, T., Tini, M., & Evans, R. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204853 · Cited by 182
“Alternatively, X-RARa fusion proteins can inhibit gene expression through non-DNA binding mechanisms such as abolishment of DNA binding and transactivation by neutrophilic di erentiation factor C/EBPa (Pabst et al., 2001; D Tenen, personal communication).”
BackgroundMcBindall—A Better Name for CCAAT/Enhancer Binding Proteins?
McKnight, S. L. (2001) · Cell · doi:10.1016/s0092-8674(01)00543-8 · Cited by 170
“The answer to this question came as a resounding yes from the recentrecognized just this week by our paragons in Stockholm—we understand the regulatory apparatus respon- work of Tenen and colleagues (Pabst et al., 2001).”
BackgroundReddy, V. A., Iwama, A., Iotzova, G., Schulz, M., Elsasser, A., Vangala, R. K., Tenen, D. G., Hiddemann, W., & Behre, G. (2002) · Blood · doi:10.1182/blood.v100.2.483 · Cited by 152
Self-citationRapino, F., Robles, E. F., Richter-Larrea, J. A., Kallin, E. M., Martinez-Climent, J. A., & Graf, T. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.03.003 · Cited by 143
“Most recently, it was shown that cancer stem cells of acute myeloid leukemia (AML) can be selectively induced to differentiate using a drug that blocks dopamine receptors, strongly inhibiting tumor formation in a xenograft mouse model (Sachlos et al., 2012).”
InfluentialPhosphorylation of C/EBPα Inhibits Granulopoiesis
Ross, S. E., Radomska, H. S., Wu, B., Zhang, P., Winnay, J. N., Bajnok, L., Wright, W. S., Schaufele, F., Tenen, D. G., & MacDougald, O. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.2.675-686.2004 · Cited by 146
Self-citationC/EBPa controls acquisition and maintenance of adult haematopoietic stem cell quiescence
Ye, M., Zhang, H., Amabile, G., Yang, H., Staber, P. B., Zhang, P., Levantini, E., Alberich-Jordà, M., Zhang, J., Kawasaki, A., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2698 · Cited by 142
Self-citationTranslational implications of somatic genomics in acute myeloid leukaemia
Meyer, S. C., & Levine, R. L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70008-7 · Cited by 161
JAM-A Acts via C/EBP-α to Promote Claudin-5 Expression and Enhance Endothelial Barrier Function
Kakogiannos, N., Ferrari, L., Giampietro, C., Scalise, A. A., Maderna, C., Ravà, M., Taddei, A., Lampugnani, M. G., Pisati, F., Malinverno, M., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.316742 · Cited by 149
Dichotomy of AML1-ETO Functions: Growth Arrest versus Block of Differentiation
Burel, S. A., Harakawa, N., Zhou, L., Pabst, T., Tenen, D. G., & Zhang, D.-E. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.16.5577-5590.2001 · Cited by 142
Self-citationStruski, S., Lagarde, S., Bories, P., Puiseux, C., Prade, N., Cuccuini, W., Pagès, M.-P., Bidet, A., Gervais, C., Lafage‐Pochitaloff, M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.267 · Cited by 143
Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics
Gregory, T. K., Wald, D. N., Chen, Y., Vermaat, J. M., Xiong, Y., & Tse, W. W. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-23 · Cited by 142
“The CCAT/Enhancer Binding Protein Alpha Gene (CEBPα) CEBPα is an essential transcription factor for granulocytic differentiation as demonstrated by CEBPα-null mice that lack mature granulocytes [40,41].”
BackgroundWang, G.-L., Iakova, P., Wilde, M., Awad, S., & Timchenko, N. A. (2004) · Genes & Development · doi:10.1101/gad.1183304 · Cited by 140
“A recent paper with Akt1/Akt2 double knockout animals showed that the ablation of these kinases reduces expression and activities of C/EBP , which correlates with impaired adipogenesis in these animals (Peng et al. 2003).”
BackgroundMiller, M., Shuman, J. D., Sebastian, T., Dauter, Z., & Johnson, P. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300417200 · Cited by 138
Current findings for recurring mutations in acute myeloid leukemia
Takahashi, S. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-36 · Cited by 160
“These mutations lead to increased translation of an alternative 30-kDa form with dominant negative activity on the full-length 42-kDa protein when they occur in the N-terminus, while C-terminal mutations result in deficient DNA binding and/or homodimerization activities [63,78].”
BackgroundMarcucci, G., Mrózek, K., & Bloomfield, C. D. (2004) · Current Opinion in Hematology · doi:10.1097/01.moh.0000149608.29685.d1 · Cited by 131
Ptasinska, A., Assi, S. A., Martinez-Soria, N., Imperato, M. R., Piper, J., Cauchy, P., Pickin, A., James, S. R., Hoogenkamp, M., Williamson, D., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.024 · Cited by 135
“Similarly to PU.1, C/EBP α upregulates its own expression in murine cells, and it was previously suggested that RUNX1/ETO interferes with C/EBP α expression by sequestering it from its promoter and thereby suppressing autoactivation (Pabst et al., 2001a).”
Self-citationGuibal, F. C., Alberich-Jorda, M., Hirai, H., Ebralidze, A., Levantini, E., Di Ruscio, A., Zhang, P., Santana-Lemos, B. A., Neuberg, D., Wagers, A. J., et al. (2009) · Blood · doi:10.1182/blood-2008-10-182071 · Cited by 126
Self-citationComplexity of CEBPA Dysregulation in Human Acute Myeloid Leukemia
Pabst, T., & Mueller, B. U. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2941 · Cited by 114
Self-citationClonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia
Parkin, B., Ouillette, P., Li, Y., Keller, J., Lam, C., Roulston, D., Li, C., Shedden, K., & Malek, S. N. (2013) · Blood · doi:10.1182/blood-2012-04-427039 · Cited by 120
Down-regulation and antiproliferative role of C/EBPalpha in lung cancer.
Halmos, B., Huettner, C. S., Kocher, O. N., Ferenczi, K., Karp, D. D., & Tenen, D. G. (2002) · PubMed · Cited by 135
Self-citationSox4 Is a Key Oncogenic Target in C/EBPα Mutant Acute Myeloid Leukemia
Zhang, H., Alberich-Jorda, M., Amabile, G., Yang, H., Staber, P. B., Di Ruscio, A., Welner, R. S., Ebralidze, A., Zhang, J., Levantini, E., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.018 · Cited by 118
“We analyzed Sox4 mRNA levels after transducing Cebpa KO LSK cells with viruses encoding either wild-type human CEBPA or a series of mutant proteins identified from human AML patients (Pabst et al., 2001).”
Self-citationRosmarin, A. G., Yang, Z., & Resendes, K. K. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2004.08.015 · Cited by 121
“Several groups have now reported C/EBPα mutations with a frequency of 7% to 11% of all AML patients [149–152].”
BackgroundAML1-ETO reprograms hematopoietic cell fate by downregulatingsclexpression
Yeh, J.-R. J., Munson, K. M., Chao, Y. L., Peterson, Q. P., MacRae, C. A., & Peterson, R. T. (2007) · Development · doi:10.1242/dev.008904 · Cited by 126
“Moreover, it has been shown that the CCAAT/enhancer-binding protein (C/ebp ) plays a crucial role in the maturation of granulocytes, and that human t(8;21) blasts express very low levels of CEBPA (Pabst et al., 2001a; Pabst et al., 2001b).”
BackgroundArber, D. A., Borowitz, M. J., Cessna, M. H., Etzell, J. E., Foucar, K. K., Hasserjian, R. P., Rizzo, J. D., Theil, K. S., Wang, S. A., Smith, A. T., et al. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0504-cp · Cited by 134
Christiansen, D. H., Andersen, M. K., Desta, F. Z., & Pedersen-Bjergaard, J. (2005) · Leukemia · doi:10.1038/sj.leu.2404009 · Cited by 132
Zhou, J., Ching, Y. Q., & Chng, W. J. (2015) · Oncotarget · doi:10.18632/oncotarget.3545 · Cited by 130
“Except for some rare types of mutations, C/EBPα mutations can be classified into two main categories: (1) N-terminal mutations that lead to premature termination of protein translation, resulting in translation of a dominant negative, short C/EBPα p30 isoform; (2) C-terminal mutations that disrupt the bZIP region, res…”
BackgroundTarlock, K., Lamble, A. J., Wang, Y., Gerbing, R. B., Ries, R. E., Loken, M. R., Brodersen, L. E., Pardo, L. M., Leonti, A. R., Smith, J. L., et al. (2021) · Blood · doi:10.1182/blood.2020009652 · Cited by 126
The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML
Eyholzer, M., Schmid, S., Wilkens, L., Mueller, B. U., & Pabst, T. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605751 · Cited by 115
“We used leukaemic Kasumi-1 cells lacking detectable amounts of endogenous CEBPA, however, containing an inducible CEBPA-ER fusion construct (Pabst et al, 2001a).”
BackgroundMethodSelf-citationC/EBPα binds and activates the PU.1 distal enhancer to induce monocyte lineage commitment
Yeamans, C., Wang, D., Paz-Priel, I., Torbett, B. E., Tenen, D. G., & Friedman, A. D. (2007) · Blood · doi:10.1182/blood-2007-03-080291 · Cited by 118
Self-citationPrognostic factors for acute myeloid leukaemia in adults - biological significance and clinical use
Liersch, R., Müller‐Tidow, C., Berdel, W. E., & Krug, U. O. (2014) · British Journal of Haematology · doi:10.1111/bjh.12750 · Cited by 140
“No clear data exist about the predictive value of genetic aberrations on PRT. Data exist showing that patients with CN-AML and FLT3-ITD benefited from an allogeneic HSCT in first CR compared to cytotoxic consolidation treatment (Bornhauser et al, 2007; Schlenk et al, 2008), which could not be validated by others (Gale…”
BackgroundInfluentialThaler, L., Gauvin, L., Joober, R., Groleau, P., de Guzman, R., Ambalavanan, A., Israel, M., Wilson, S., & Steiger, H. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.04.010 · Cited by 117
Porse, B. T., Bryder, D., Theilgaard-Mönch, K., Hasemann, M. S., Anderson, K., Damgaard, I., Jacobsen, S. E. W., & Nerlov, C. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050067 · Cited by 117
Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia
Wakita, S., Sakaguchi, M., Oh, I., Kako, S., Toya, T., Najima, Y., Doki, N., Kanda, J., Kuroda, J., Mori, S., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004292 · Cited by 117
Heath, V., Suh, H. C., Holman, M., Renn, K., Gooya, J. M., Parkin, S., Klarmann, K. D., Ortiz, M., Johnson, P., & Keller, J. (2004) · Blood · doi:10.1182/blood-2003-11-3963 · Cited by 114
Schoch, C., Haferlach, T., Bursch, S., Gerstner, D., Schnittger, S., Dugas, M., Kern, W., Löffler, H., & Hiddemann, W. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10088 · Cited by 118
“…such as internal tandem duplications of the MLL gene, length mutations of the FLT3 gene, and point mutations within the AML1 and CEBPA genes have been described in AML with normal karyotypes (Nakao et al., 1996; Yu et al., 1996; Osato et al., 1999; Schnittger et al., 2000a,b; Pabst et al., 2001).”
BackgroundSelf-citationSegmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia
Raghavan, M., Smith, L., Lillington, D. M., Chaplin, T., Kakkas, Ι., Molloy, G. Y., Chelala, C., Cazier, J., Cavenagh, J. D., Fitzgibbon, J., et al. (2008) · Blood · doi:10.1182/blood-2008-01-132431 · Cited by 114
Transcription factor fusions in acute leukemia: variations on a theme
Scandura, J. M., Boccuni, P., Cammenga, J., & Nimer, S. D. (2002) · Oncogene · doi:10.1038/sj.onc.1205315 · Cited by 132
“Acquired dominant negative mutations of C/EBPa have been reported, and may occur in up to 17% of M2 AML with a normal karyotype (Pabst et al., 2001b).”
BackgroundResultInfluentialTranslation acrobatics: how cancer cells exploit alternate modes of translational initiation
Sriram, A., Bohlen, J., & Teleman, A. A. (2018) · EMBO reports · doi:10.15252/embr.201845947 · Cited by 110
Genetic predispositions to childhood leukemia
Stieglitz, E., & Loh, M. L. (2013) · Therapeutic Advances in Hematology · doi:10.1177/2040620713498161 · Cited by 127
“1 and encodes the granulocytic differentiation factor C/EBPα, which belongs to the bZIP family of proteins and plays a role in myeloid differentiation [Pabst et al. 2001].”
BackgroundC/EBPα in normal and malignant myelopoiesis
Friedman, A. D. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1764-6 · Cited by 101
“The protein-coding CEBPA ORF is mutated in approximately 10 % of AML cases, most often those with FAB M1 or M2 morphology lacking t(8;21) [115, 116].”
BackgroundMolecular Mechanism of CCAAT-Enhancer Binding Protein Recruitment by the TRIB1 Pseudokinase
Murphy, J. M., Nakatani, Y., Jamieson, S. A., Dai, W., Lucet, I. S., & Mace, P. D. (2015) · Structure · doi:10.1016/j.str.2015.08.017 · Cited by 121
Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2
Snaddon, J., Smith, M. L., Neat, M., Cambal‐Parrales, M., Dixon‐McIver, A., Arch, R., Amess, J. A., Rohatiner, A. Z., Lister, T. A., & Fitzgibbon, J. (2003) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10185 · Cited by 110
“The RUNX1-CBFA2T1 fusion protein, which occurs in 10–15% of cases of AML, causes an eightfold down-regulation of CEBPA expression (Pabst et al., 2001b).”
BackgroundResultInfluentialFröhling, S., Skelin, S., Liebisch, C., Scholl, C., Schlenk, R. F., Döhner, H., & Döhner, K. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.155 · Cited by 109
Diagnostic and Prognostic Value of Cytogenetics in Acute Myeloid Leukemia
Grimwade, D. J., & Mrózek, K. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.09.018 · Cited by 120
The Role of C/EBPβ in Mammary Gland Development and Breast Cancer
Grimm, S. L., & Rosen, J. M. (2003) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1025900908026 · Cited by 127
Mutational landscape of AML with normal cytogenetics: Biological and clinical implications
Martelli, M. P., Sportoletti, P., Tiacci, E., Martelli, M. F., & Falini, B. (2012) · Blood Reviews · doi:10.1016/j.blre.2012.11.001 · Cited by 126
Driver mutations in acute myeloid leukemia
Kishtagari, A., Levine, R. L., & Viny, A. D. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000567 · Cited by 112
A tumor suppressor role for C/EBPα in solid tumors: more than fat and blood
Lourenço, A. R., & Coffer, P. J. (2017) · Oncogene · doi:10.1038/onc.2017.151 · Cited by 113
Transcriptional dysregulation during myeloid transformation in AML
Pabst, T., & Mueller, B. U. (2007) · Oncogene · doi:10.1038/sj.onc.1210765 · Cited by 120
“Also, at least one CEBPA mutation in AML has been reported whose activation potential in transfection assays exceeded several fold that of the wild-type construct (Pabst et al., 2001b).”
BackgroundInfluentialSelf-citationCCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia
Truong, B.-T. H. (2003) · Blood · doi:10.1182/blood-2002-05-1374 · Cited by 103
Self-citationCCAAT/enhancer binding proteins in normal mammary development and breast cancer
Zahnow, C. A. (2002) · Breast Cancer Research · doi:10.1186/bcr428 · Cited by 112
C/EBP transcription factors in the lung epithelium
Cassel, T. N., & Nord, M. (2003) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00023.2003 · Cited by 107
Baldus, C. D., Mrózek, K., Marcucci, G., & Bloomfield, C. D. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06566.x · Cited by 102
“Likewise, in a smaller study (Bienz et al, 2005), CEBPA mutations, FLT3-ITD status and BAALC expression were independent prognostic factors for DFS and OS.”
BackgroundInfluentialSecondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA)
Brown, A. L., Hahn, C. N., & Scott, H. S. (2020) · Blood · doi:10.1182/blood.2019000937 · Cited by 106
Chang, J. S., Santhanam, R., Trotta, R., Neviani, P., Eiring, A. M., Briercheck, E., Ronchetti, M., Roy, D. C., Calabretta, B., Caligiuri, M. A., et al. (2007) · Blood · doi:10.1182/blood-2007-03-078303 · Cited by 98
Autophagy in acute leukemias: A double-edged sword with important therapeutic implications
Evangelisti, C., Evangelisti, C., Chiarini, F., Lonetti, A., Buontempo, F., Neri, L. M., McCubrey, J. A., & Martelli, A. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.09.023 · Cited by 106
The Changing Mutational Landscape of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Larsson, C. A., Cote, G., & Quintás-Cardama, A. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0695 · Cited by 94
Effect of transcription-factor concentrations on leukemic stem cells
Rosenbauer, F., Koschmieder, S., Steidl, U., & Tenen, D. G. (2005) · Blood · doi:10.1182/blood-2005-02-0717 · Cited by 98
Self-citationKeeshan, K., Santilli, G., Corradini, F., Perrotti, D., & Calabretta, B. (2003) · Blood · doi:10.1182/blood-2003-02-0477 · Cited by 98
Guo, H. W., Ma, O., Speck, N. A., & Friedman, A. D. (2012) · Blood · doi:10.1182/blood-2011-12-397091 · Cited by 107
D'Alo', F., Johansen, L. M., Nelson, E. A., Radomska, H. S., Evans, E. K., Zhang, P., Nerlov, C., & Tenen, D. G. (2003) · Blood · doi:10.1182/blood-2003-02-0479 · Cited by 98
Self-citationHelbling, D. C., Mueller, B. U., Timchenko, N. A., Schardt, J., Eyer, M., Betts, D. R., Jotterand, M., Meyer‐Monard, S., Fey, M. F., & Pabst, T. (2005) · Blood · doi:10.1182/blood-2004-11-4392 · Cited by 104
Self-citationDown-Regulation and Growth Inhibitory Role of C/EBPα in Breast Cancer
Gery, S., Tanosaki, S., Bose, S., Bose, N., Vadgama, J. V., & Koeffler, H. P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2625 · Cited by 104
C/EBPα and the pathophysiology of acute myeloid leukemia
Mueller, B. U., & Pabst, T. (2005) · Current Opinion in Hematology · doi:10.1097/01.moh.0000190110.08156.96 · Cited by 112
Self-citationThe splicing factor RBM25 controls MYC activity in acute myeloid leukemia
Ge, Y. C., Schuster, M. B., Pundhir, S., Rapin, N., Bagger, F. O., Sidiropoulos, N., Hashem, N. B., & Porse, B. T. (2019) · Nature Communications · doi:10.1038/s41467-018-08076-y · Cited by 99
C/EBPα: A tumour suppressor in multiple tissues?
Schuster, M. B., & Porse, B. T. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.02.003 · Cited by 99
Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia
Meshinchi, S., & Arceci, R. J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-3-341 · Cited by 97
Russell, L. J., Enshaei, A., Jones, L., Erhorn, A., Mašić, D., Bentley, H., Laczko, K. S., Fielding, A. K., Goldstone, A. H., Goulden, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.3242 · Cited by 96
Suh, H. C., Gooya, J., Renn, K., Friedman, A. D., Johnson, P. F., & Keller, J. R. (2006) · Blood · doi:10.1182/blood-2005-06-2216 · Cited by 95
Prognostic Implications of Gene Mutations in Acute Myeloid Leukemia With Normal Cytogenetics
Gaidzik, V. I., & Döhner, K. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.005 · Cited by 110
Reilly, J. T. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05236.x · Cited by 115
“Mutual exclusivity is also a feature of class II mutations since mutations of C/EBF and PU.1 are rare in the CBF leukaemias (Pabst et al, 2001a; Mueller et al, 2002).”
BackgroundDeguchi, K., & Gilliland, D. G. (2002) · Leukemia · doi:10.1038/sj.leu.2402500 · Cited by 106
Epigenetics in Cancer: A Hematological Perspective
Stahl, M. F., Kohrman, N., Gore, S. D., Kim, T. K., Zeidan, A. M., & Prébet, T. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006193 · Cited by 99
Vanhees, K., Coort, S., Ruijters, E. J. B., Godschalk, R. W. L., van Schooten, F. J., & van Doorn‐Khosrovani, S. B. V. W. (2011) · The FASEB Journal · doi:10.1096/fj.10-172155 · Cited by 87
“Microarray analysis showed that several genes, whose lack of expression associates with defects in granulocytic lineage, were down-regulated in the genistein group [e.g., Cebpa (27), JunB (28), and Icam1 (29)].”
InfluentialAn autonomous CEBPA enhancer specific for myeloid-lineage priming and neutrophilic differentiation
Avellino, R., Havermans, M., Erpelinck, C., Sanders, M. A., Hoogenboezem, R., van de Werken, H. J. G., Rombouts, E., van Lom, K., van Strien, P. M. H., Gebhard, C., et al. (2016) · Blood · doi:10.1182/blood-2016-01-695759 · Cited by 83
Modulating transcription factor activity: Interfering with protein-protein interaction networks
François, M., Donovan, P., & Fontaine, F. R. (2018) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2018.07.019 · Cited by 95
Maximal STAT5-Induced Proliferation and Self-Renewal at Intermediate STAT5 Activity Levels
Wierenga, A. T. J., Vellenga, E., & Schuringa, J. J. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01025-08 · Cited by 103
Figueroa, M. E., Wouters, B. J., Skrabanek, L., Glass, J., Li, Y., Erpelinck-Verschueren, C. A. J., Langerak, A. W., Löwenberg, B., Fazzari, M., Greally, J. M., et al. (2009) · Blood · doi:10.1182/blood-2008-08-172387 · Cited by 91
The CCAAT Enhancer-binding Protein α (C/EBPα) Requires a SWI/SNF Complex for Proliferation Arrest
Müller, C., Calkhoven, C. F., Sha, X., & Leutz, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312709200 · Cited by 105
Hughes, J. M., Legnini, I., Salvatori, B., Masciarelli, S., Marchioni, M., Fazi, F., Morlando, M., Bozzoni, I., & Fatica, A. (2015) · Oncotarget · doi:10.18632/oncotarget.4069 · Cited by 96
“The ratio of p30/p42 is critical for granulopoiesis as the p30 protein fails to induce differentiation and increases cell proliferation of myeloid progenitors [3, 8].”
Helbling, D., Mueller, B. U., Timchenko, N. A., Hagemeijer, A., Jotterand, M., Meyer‐Monard, S., Lister, A. T., Rowley, J. D., Huegli, B., Fey, M. F., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404731101 · Cited by 100
Self-citationInduction of C/EBPα activity alters gene expression and differentiation of human CD34+ cells
Cammenga, J., Mulloy, J. C., Berguido, F. J., MacGrogan, D., Viale, A., & Nimer, S. D. (2003) · Blood · doi:10.1182/blood-2002-05-1546 · Cited by 85
Chyla, B., Moreno–Miralles, I., Steapleton, M. A., Thompson, M. A., Bhaskara, S., Engel, M. E., & Hiebert, S. W. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00404-08 · Cited by 91
Signal Transduction of Oncogenic Flt3
Choudhary, C., Müller‐Tidow, C., Berdel, W. E., & Serve, H. L. (2005) · International Journal of Hematology · doi:10.1532/ijh97.05090 · Cited by 101
Tiosano, D., Wildbaum, G., Gepstein, V., Verbitsky, O., Weisman, Y., Karin, N., & Eztioni, A. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3858 · Cited by 94
Si, J., & Collins, S. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2509 · Cited by 93
Staffas, A., Kanduri, M., Hovland, R., Rosenquist, R., Ommen, H. B., Abrahamsson, J., Forestier, E., Jahnukainen, K., Jónsson, Ó. G., Zeller, B., et al. (2011) · Blood · doi:10.1182/blood-2011-05-353185 · Cited by 86
The multifaceted functions of C/EBPα in normal and malignant haematopoiesis
Ohlsson, E., Schuster, M. B., Hasemann, M. S., & Porse, B. T. (2015) · Leukemia · doi:10.1038/leu.2015.324 · Cited by 92
Selecting initial treatment of acute myeloid leukaemia in older adults
Podoltsev, N. A., Stahl, M. F., Zeidan, A. M., & Gore, S. D. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.09.005 · Cited by 91
Molecular Genetic Markers in Acute Myeloid Leukemia
Yohe, S. L. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4030460 · Cited by 97
“dominant negative effect [28].”
Clinical implications of molecular markers in acute myeloid leukemia
Käyser, S., & Levis, M. J. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13172 · Cited by 90
Behre, G., Singh, S. M., Liu, H., Bortolin, L. T., Christopeit, M., Radomska, H. S., Rangatia, J., Hiddemann, W., Friedman, A. D., & Tenen, D. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202301200 · Cited by 84
“(Pabst et al., 2001a) Furthermore, AML1-ETO associates with C/EBPα, inhibits C/EBPα dependent transcription of myeloid cell specific rat defensin NP-3 promoter, and blocks granulocytic differentiation.”
BackgroundSelf-citationMolecular genetics in acute myeloid leukemia
Bacher, U., Schnittger, S., & Haferlach, T. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833ed806 · Cited by 74
Self-citationAkagi, T., Ogawa, S., Dugas, M., Kawamata, N., Yamamoto, G., Nannya, Y., Sanada, M., Miller, C. W., Yung, A., Schnittger, S., et al. (2009) · Haematologica · doi:10.3324/haematol.13024 · Cited by 82
“About 10-15% of AML samples have inactivating mutations of C/EBPα whose wild-type function is to enhance differentiation.(17,18) Nucleophosmin1 (NPM1) is mutated in 50-60% of AML samples with normal karyotype.”
BackgroundSelf-citationAcute Myeloid Leukemia Diagnosis in the 21st Century
Betz, B. L., & Hess, J. L. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0245-ra.1 · Cited by 96
Lavallée, V., Krošl, J., Lemieux, S., Boucher, G., Gendron, P., Pabst, C., Boivin, I., Marinier, A., Guidos, C. J., Meloche, S., et al. (2016) · Blood · doi:10.1182/blood-2016-03-705053 · Cited by 79
Geletu, M., Balkhi, M. Y., Zada, A. A. P., Christopeit, M., Pulikkan, J. A., Trivedi, A. K., Tenen, D. G., & Behre, G. (2007) · Blood · doi:10.1182/blood-2007-01-071035 · Cited by 88
Self-citationDisruption of Hepatic C/EBPα Results in Impaired Glucose Tolerance and Age-dependent Hepatosteatosis
Inoue, Y., Inoue, J., Lambert, G., Yim, S. H., & Gonzalez, F. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405177200 · Cited by 80
Metadata
- Authors
- Pabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G.
- Affiliations
- Harvard University (US)
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Tenen, Daniel G.
- Venue
- Nature Genetics
- Published
- 2001-03
- Volume
- 27
- Issue
- 3
- Pages
- 263-270
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2100088478
- Cited by
- 901
- References
- 33
- Citations by year
- 2026: 15 · 2025: 11 · 2024: 23 · 2023: 21 · 2022: 30 · 2021: 22 · 2020: 27 · 2019: 17 · 2018: 22 · 2017: 27 · 2016: 29 · 2015: 47 · 2014: 37 · 2013: 34 · 2012: 50
- FWCI
- 23.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL056745, HL56745)
- National Cancer Institute (CA-72009, P01CA072009)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Blood disorders and treatments
- Keywords
- CEBPA, C/EBPα, acute myeloid leukemia, dominant negative mutation, heterozygous mutation, transcription factors, granulocytic differentiation, DNA binding, transcriptional activation, N-terminal truncation
- MeSH terms
- Base Sequence, Cell Differentiation, Cell Nucleus, DNA, Neoplasm, Genes, Dominant, Granulocytes, Heterozygote, Humans, Mutation, Neutrophils, Leukemia, Myeloid, Acute, Transcriptional Activation, Sequence Deletion, DNA Primers, CCAAT-Enhancer-Binding Protein-alpha, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.